When informed of one of the events mentioned in Article L. 5212-2, the Director of the Agence nationale de sécurité du médicament et des produits de santé (French National Agency for the Safety of Medicines and Health Products) will, if possible, carry out an assessment jointly with the manufacturer of the device in question and, if necessary, take the measures provided for in Articles L. 5312-1 to L. 5312-3.